Skip to content

Endovascular Treatment of Primary Common FEmoral Artery atheroSclerotic Disease wiTh IntraVAscular Litothripsy

Endovascular Treatment of Primary Common FEmoral Artery atheroSclerotic Disease wiTh IntraVAscular Litothripsy: the FESTIVAL Registry

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05821829
Acronym
FESTIVAL
Enrollment
150
Registered
2023-04-20
Start date
2023-05-01
Completion date
2025-05-01
Last updated
2023-05-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Common Femoral Artery Occlusion, Common Femoral Artery Stenosis, Critical Limb-Threatening Ischemia, Peripheral Arterial Disease

Brief summary

Prospective, nonrandomized, multicenter, national, multidisciplinary, real-world data collection with the aim to evaluate the short-term safety and efficacy of intravascular lithotripsy in the treatment of steno-obstructive disease of the common femoral artery

Interventions

DEVICEIntravascular litothripsy (IVL)

endovascular treatment of primary common femoral artery atherosclerotic disease with intravascular litothripsy

Sponsors

University of Pisa
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
No

Inclusion criteria

1. Patients with peripheral arterial disease (Rutherford class 3-6) 2. Presence of a steno-obstructive lesion of the common femoral artery (Azema classification 1-3) 3. Possible endovascular treatment of both the iliac axis and/or femoro-distal vessels 4. Possible post-dilatation with plain or drug-coated balloon angioplasty

Exclusion criteria

1. Concomitant open surgery (ilio-femoral or femoro-distal bypass) 2. Presence of a steno-obstructive lesion of the common femoral artery in previous open surgery (Azema classification 4) 3. Presence of a steno-obstructive lesion of the common femoral artery after a previous endovascular procedure

Design outcomes

Primary

MeasureTime frameDescription
Clinically driven freedom from target lesion restenosis (cdTLR)1 month / 6 months / 1 yearrestenosis resulting in vessel occlusion or stenosis with maximum PSV \> 2.5 m/sec
Primary patency1 month / 6 months / 1 yearpatency of the treated vessel in the absence of a restenosis \>30%
Primary assisted patency1 month / 6 months / 1 yearpatency of the treated vessel after one or more endovascular reinterventions
Secondary patency1 month / 6 months / 1 yearpatency of the treated vessel after occlusione and treatment by surgical or endovascular means
Technical successIntraproceduralinsertion/use of the device after crossing the steno-obstructive lesion and its removal without complications, restoration of vessel patency in the absence of stenosis/acute recoil \>30%, rupture/perforation of the common femoral artery, need for a bailout stenting
Clinical successIntraprocedural / 1 monthabsence of intraprocedural complications including distal embolization and improvement of at least 1 Rutherford class assessed 1 month after the procedure

Secondary

MeasureTime frame
Patency of profunda femoris1 month / 6 months / 1 year
Limb salvage1 month / 6 months / 1 year
Freedom from any reinterventions1 month / 6 months / 1 year

Countries

Italy

Contacts

Primary ContactNicola Troisi, Prof
nicola.troisi@unipi.it00393280205530

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026